Related Experiment Video
Updated: Nov 19, 2025
05:19
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
Published on: July 7, 2023
2.9K
Variable- versus constant-frequency sacral neuromodulation in black-zone overactive bladder patients: a study
Lingfeng Meng1, Zijian Tian1, Tongxiang Diao1
1Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Translational Andrology and Urology
|February 3, 2021
Summary
This study evaluates variable-frequency stimulation sacral neuromodulation (VFS-SNM) for overactive bladder (OAB) patients resistant to standard treatment. VFS-SNM shows promise as a new therapeutic option for these challenging cases.
Area of Science:
- Urology
- Neurology
- Medical Devices
Background:
- Sacral neuromodulation (SNM) is effective for overactive bladder (OAB), but some patients experience recurrent symptoms.
- These 'black-zone' OAB patients show limited improvement even with adjusted stimulation and oral medications.
- Standard SNM uses constant-frequency stimulation (CFS), while variable-frequency stimulation (VFS) is a novel approach.
Purpose of the Study:
- To evaluate the efficacy and safety of VFS-SNM compared to CFS-SNM in black-zone OAB patients.
- To provide high-quality clinical evidence for a potential new treatment option.
Main Methods:
- A multicenter, prospective, randomized, blinded, self-controlled trial.
- 12-week follow-up period comparing VFS-SNM and CFS-SNM groups.
- Primary endpoint: comparative effectiveness; Secondary endpoints: OAB symptom score, QOL, and VAS changes.
Main Results:
- Previous studies and preliminary results suggest VFS-SNM may benefit black-zone OAB patients.
- Twelve weeks of VFS-SNM demonstrated effectiveness in 40% of patients.
- Sample size calculated at 37 patients per group, with 80% power and 0.05 significance level.
Conclusions:
- This is the first randomized controlled trial assessing VFS-SNM for black-zone OAB.
- VFS-SNM offers a potential new clinical option for patients with refractory OAB.
- The study aims to provide robust evidence for VFS-SNM's efficacy and safety.
